Trial Profile
A Phase 1, Open-Label, Randomized, 4-Way Crossover Study in Subjects With Chronic Hepatitis B Virus Infection to Assess Pharmacokinetics (Fasted/Fed), Safety, Tolerability and Pharmacodynamics of Single Oral Doses of Farnesoid X Receptor Agonist EYP001a
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Vonafexor (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors ENYO Pharma
- 02 Mar 2018 Status changed from recruiting to completed.
- 30 Oct 2017 New trial record